Cell and gene therapy approaches for cardiac vascularization

Cells

Volumn 1, Issue 4, 2012, Pages 961-975

  Melly, Ludovic ^a   Boccardo, Stefano ^b   Eckstein, Friedrich ^a   Banfi, Andrea ^a   Marsano, Anna ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

Author keywords

Angiogenesis; Cardiac ischemia; Cardiac tissue engineering; Cell therapy; Cell based gene therapy; Gene therapy; VEGF controlled release

Indexed keywords

ANGIOPOIETIN 1; CD8 ANTIGEN; NEUROPILIN 1; PLATELET DERIVED GROWTH FACTOR BB; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN;

ANGIOGENESIS; CELL BASED GENE THERAPY; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CELL THERAPY; CLINICAL TRIAL (TOPIC); CORONARY ARTERY LIGATION; EXTRACELLULAR MATRIX; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENETIC MANIPULATION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; MICROENVIRONMENT; NONHUMAN; PROTEIN EXPRESSION; REVIEW; VASCULARIZATION;

EID: 84904720362     PISSN: None     EISSN: 20734409     Source Type: Journal    
DOI: 10.3390/cells1040961     Document Type: Review

References (73)

1. Roger, V.L.; Go, A.S.; Lloyd-Jones, D.M.; Benjamin, E.J.; Berry, J.D.; Borden, W.B.; Bravata, D.M.; Dai, S.; Ford, E.S.; Fox, C.S.; et al., Heart disease and stroke statistics 2012 update: A report from the American Heart Association. Circulation 2012, 125, e2-e220.
2. Pries, A.R.; Höpfner, M.; le Noble, F.; Dewhirst, M.W.; Secomb, T.W. The shunt problem: control of functional shunting in normal and tumour vasculature. Nat. Rev. Cancer 2010, 10, 587-593.
3. Rissanen, T.T.; Korpisalo, P.; Markkanen, J.E.; Liimatainen, T.; Ordén, M.R.; Kholová, I.; de Goede, A.; Heikura, T.; Gröhn, O.H.; Ylä-Herttuala, S. Blood flow remodels growing vasculature during vascular endothelial growth factor gene therapy and determines between capillary arterialization and sprouting angiogenesis. Circulation 2005, 112, 3937-3946.
4. Giacca, M.; Zacchigna, S. VEGF gene therapy: Therapeutic angiogenesis in the clinic and beyond. Gene Ther. 2012, 19, 622-629.
5. Ferrara, N.; Carver-Moore, K.; Chen, H.; Dowd, M.; Lu, L.; O'Shea, K.S.; Powell-Braxton, L.; Hillan, K.J.; Moore, M.W. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996, 380, 439-442.
6. Haigh, J.J.; Gerber, H.P.; Ferrara, N.; Wagner, E.F. Conditional inactivation of VEGF-A in areas of collagen2a1 expression results in embryonic lethality in the heterozygous state. Development 2000, 127, 1445-1453.
7. Mitsos, S.; Katsanos, K.; Koletsis, E.; Kagadis, G.C.; Anastasiou, N.; Diamantopoulos, A.; Karnabatidis, D.; Dougenis, D. Therapeutic angiogenesis for myocardial ischemia revisited: basic biological concepts and focus on latest clinical trials. Angiogenesis. 2012, 15, 1-22.
8. Gerhardt, H.; Golding, M.; Fruttiger, M.; Ruhrberg, C.; Lundkvist, A.; Abramsson, A.; Jeltsch, M.; Mitchell, C.; Alitalo, K.; Shima, D.; et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J. Cell. Biol. 2003, 161, 1163-1177.
9. Hellstrom, M.; Phng, L.K.; Hofmann, J.J.; Wallgard, E.; Coultas, L.; Lindblom, P.; Alva, J.; Nilsson, A.K.; Karlsson, L.; Gaiano, N.; et al. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 2007, 445, 776-780.
10. Park, J.E.; Keller, G.A.; Ferrara, N. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol. Biol. Cell. 1993, 4, 1317-1326.
11. Gaengel, K.; Genove, G.; Armulik, A.; Betsholtz, C. Endothelial-mural cell signaling in vascular development and angiogenesis. Arterioscler. Thromb. Vasc. Biol. 2009, 29, 630-638.
12. Reginato, S.; Gianni-Barrera, R.; Banfi, A. Taming of the wild vessel: Promoting vessel stabilization for safe therapeutic angiogenesis. Biochem. Soc. Trans. 2011, 39, 1654-1658.
13. Zacchigna, S.; Pattarini, L.; Zentilin, L.; Moimas, S.; Carrer, A.; Sinigaglia, M.; Arsic, N.; Tafuro, S.; Sinagra, G.; Giacca, M. Bone marrow cells recruited through the neuropilin-1 receptor promote arterial formation at the sites of adult neoangiogenesis in mice. J. Clin. Invest. 2008, 118, 2062-2075.
14. Ozawa, C.R.; Banfi, A.; Glazer, N.L.; Thurston, G.; Springer, M.L.; Kraft, P.E.; McDonald, D.M.; Blau, H.M. Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. J. Clin. Invest. 2004, 113, 516-527.
15. Pettersson, A.; Nagy, J.A.; Brown, L.F.; Sundberg, C.; Morgan, E.; Jungles, S.; Carter, R.; Krieger, J.E.; Manseau, E.J.; Harvey, V.S.; et al. Heterogeneity of the angiogenic response induced in different normal adult tissues by vascular permeability factor/vascular endothelial growth factor. Lab Invest. 2000, 80, 99-115.
16. Springer, M.L.; Chen, A.S.; Kraft, P.E.; Bednarski, M.; Blau, H.M. VEGF gene delivery to muscle: potential role for vasculogenesis in adults. Mol. Cell. 1998, 2, 549-558.
17. Dor, Y.; Djonov, V.; Abramovitch, R.; Itin, A.; Fishman, G.I.; Carmeliet, P.; Goelman, G.; Keshet, E. Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy. EMBO J. 2002, 21, 1939-1947.
18. Carmeliet, P. VEGF gene therapy: stimulating angiogenesis or angioma-genesis? Nat. Med. 2000, 6, 1102-1103.
19. Lee, R.J.; Springer, M.L.; Blanco-Bose, W.E.; Shaw, R.; Ursell, P.C.; Blau, H.M. VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation 2000, 102, 898-901.
20. Schwarz, E.R.; Speakman, M.T.; Patterson, M.; Hale, S.S.; Isner, J.M.; Kedes, L.H.; Kloner, R.A. Evaluation of the effects of intramyocardial injection of DNA expressing vascular endothelial growth factor (VEGF) in a myocardial infarction model in the rat--angiogenesis and angioma formation. J. Am. Coll. Cardiol. 2000, 35, 1323-1330.
21. Banfi, A.; von, D.G.; Blau, H.M. Critical role of microenvironmental factors in angiogenesis. Curr. Atheroscler. Rep. 2005, 7, 227-234.
22. Karvinen, H.; Yla-Herttuala, S. New aspects in vascular gene therapy. Curr. Opin. Pharmacol. 2010, 10, 208-211.
23. Yla-Herttuala, S.; Markkanen, J.E.; Rissanen, T.T. Gene therapy for ischemic cardiovascular diseases: Some lessons learned from the first clinical trials. Trends Cardiovasc. Med. 2004, 14, 295-300.
24. von Degenfeld, G.; Banfi, A.; Springer, M.L.; Wagner, R.A.; Jacobi, J.; Ozawa, C.R.; Merchant, M.J.; Cooke, J.P.; Blau, H.M. Microenvironmental VEGF distribution is critical for stable and functional vessel growth in ischemia. FASEB J. 2006, 20, 2657-2659.
25. Gianni-Barrera, R.; Trani, M.; Fontanellaz, C.; Heberer, M.; Djonov, V.; Hlushchuk, R.; Banfi, A. VEGF over-expression in skeletal muscle induces angiogenesis by intussusception rather than sprouting. Angiogenesis 2012, doi:10.1007/s10456-012-9304-y.
26. Tafuro, S.; Ayuso, E.; Zacchigna, S.; Zentilin, L.; Moimas, S.; Dore, F.; Giacca, M. Inducible adeno-associated virus vectors promote functional angiogenesis in adult organisms via regulated vascular endothelial growth factor expression. Cardiovasc. Res. 2009, 83, 663-671.
27. Ptaszek, L.M.; Mansour, M.; Ruskin, J.N.; Chien, K.R. Towards regenerative therapy for cardiac disease. Lancet 2012, 379, 933-942.
28. Cashman, T.J.; Gouon-Evans, V.; Costa, K.D. Mesenchymal Stem Cells for Cardiac Therapy: Practical Challenges and Potential Mechanisms. Stem Cell Rev. 2012.
29. Botta, R.; Gao, E.; Stassi, G.; Bonci, D.; Pelosi, E.; Zwas, D.; Patti, M.; Colonna, L.; Baiocchi, M.; Coppola, S.; et al. Heart infarct in NOD-SCID mice: therapeutic vasculogenesis by transplantation of human CD34+ cells and low dose CD34+KDR+ cells. FASEB J. 2004, 18, 1392-1394.
30. Kocher, A.A.; Schuster, M.D.; Szabolcs, M.J.; Takuma, S.; Burkhoff, D.; Wang, J.; Homma, S.; Edwards, N.M.; Itescu, S. Neovascularization of ischemic myocardium by human bone-marrowderived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat. Med. 2001, 7, 430-436.
31. Bartunek, J.; Vanderheyden, M.; Vandekerckhove, B.; Mansour, S.; De Bruyne, B.; De Bondt, P.; Van Haute, I.; Lootens, N.; Heyndrickx, G.; Wijns, W. Intracoronary injection of CD133-positive enriched bone marrow progenitor cells promotes cardiac recovery after recent myocardial infarction: feasibility and safety. Circulation 2005, 112, I178-183.
32. Stamm, C.; Westphal, B.; Kleine, H.D.; Petzsch, M.; Kittner, C.; Klinge, H.; Schumichen, C.; Nienaber, C.A.; Freund, M.; Steinhoff, G. Autologous bone-marrow stem-cell transplantation for myocardial regeneration. Lancet 2003, 361, 45-46.
33. Choi, Y.H.; Kurtz, A.; Stamm, C. Mesenchymal stem cells for cardiac cell therapy. Hum. Gene Ther. 2011, 22, 3-17.
34. Asahara, T.; Kawamoto, A.; Masuda, H. Concise review: Circulating endothelial progenitor cells for vascular medicine. Stem Cells 2011, 29, 1650-1655.
35. da Silva Meirelles, L.; Caplan, A.I.; Nardi, N.B. In search of the in vivo identity of mesenchymal stem cells. Stem Cells 2008, 26, 2287-2299.
36. Li, Z.; Guo, J.; Chang, Q.; Zhang, A. Paracrine role for mesenchymal stem cells in acute myocardial infarction. Biol. Pharm. Bull. 2009, 32, 1343-1346.
37. Poncelet, A.J.; Hiel, A.L.; Vercruysse, J.; Hermans, D.; Zech, F.; Gianello, P. Intracardiac allogeneic mesenchymal stem cell transplantation elicits neo-angiogenesis in a fully immunocompetent ischaemic swine model. Eur. J. Cardiothorac. Surg. 2010, 38, 781-787.
38. Rissanen, T.T.; Yla-Herttuala, S. Current status of cardiovascular gene therapy. Mol. Ther. 2007, 15, 1233-1247.
39. Suzuki, R.; Oda, Y.; Utoguchi, N.; Maruyama, K. Progress in the development of ultrasoundmediated gene delivery systems utilizing nano-and microbubbles. J. Control. Release 2011, 149, 36-41.
40. The Journal of Gene Medicine: Gene Therapy Clinical Trials Worldwide. Available online: http://www.abedia.com/wiley/vectors.php (accessed on 15 October 2012).
41. Wu, Z.; Asokan, A.; Samulski, R.J. Adeno-associated virus serotypes: Vector toolkit for human gene therapy. Mol Ther 2006, 14, 316-327.
42. Kay, M.A. State-of-the-art gene-based therapies: the road ahead. Nat. Rev. Genet. 2011, 12, 316-328.
43. Pacak, C.A.; Byrne, B.J. AAV vectors for cardiac gene transfer: experimental tools and clinical opportunities. Mol. Ther. 2011, 19, 1582-1590.
44. Korpisalo, P.; Yla-Herttuala, S. Stimulation of functional vessel growth by gene therapy. Integr. Biol. (Camb.) 2010, 2, 102-112.
45. Korpisalo, P.; Karvinen, H.; Rissanen, T.T.; Kilpijoki, J.; Marjomaki, V.; Baluk, P.; McDonald, D.M.; Cao, Y.; Eriksson, U.; Alitalo, K.; et al. Vascular endothelial growth factor-A and plateletderived growth factor-B combination gene therapy prolongs angiogenic effects via recruitment of interstitial mononuclear cells and paracrine effects rather than improved pericyte coverage of angiogenic vessels. Circ. Res. 2008, 103, 1092-1099.
46. Kupatt, C.; Hinkel, R.; Pfosser, A.; El-Aouni, C.; Wuchrer, A.; Fritz, A.; Globisch, F.; Thormann, M.; Horstkotte, J.; Lebherz, C.; et al. Cotransfection of vascular endothelial growth factor-A and platelet-derived growth factor-B via recombinant adeno-associated virus resolves chronic ischemic malperfusion role of vessel maturation. J. Am. Coll. Cardiol. 2010, 56, 414-422.
47. Banfi, A.; von Degenfeld, G.; Gianni-Barrera, R.; Reginato, S.; Merchant, M.J.; McDonald, D.M.; Blau, H.M. Therapeutic angiogenesis due to balanced single-vector delivery of VEGF and PDGFBB. FASEB J. 2012, 26, 2486-2497.
48. Li, X.; Tjwa, M.; Van Hove, I.; Enholm, B.; Neven, E.; Paavonen, K.; Jeltsch, M.; Juan, T.D.; Sievers, R.E.; Chorianopoulos, E.; et al. Reevaluation of the role of VEGF-B suggests a restricted role in the revascularization of the ischemic myocardium. Arterioscler. Thromb. Vasc. Biol. 2008, 28, 1614-1620.
49. Lahteenvuo, J.E.; Lahteenvuo, M.T.; Kivela, A.; Rosenlew, C.; Falkevall, A.; Klar, J.; Heikura, T.; Rissanen, T.T.; Vahakangas, E.; Korpisalo, P.; et al. Vascular endothelial growth factor-B induces myocardium-specific angiogenesis and arteriogenesis via vascular endothelial growth factor receptor-1-and neuropilin receptor-1-dependent mechanisms. Circulation 2009, 119, 845-856.
50. Karpanen, T.; Bry, M.; Ollila, H.M.; Seppanen-Laakso, T.; Liimatta, E.; Leskinen, H.; Kivela, R.; Helkamaa, T.; Merentie, M.; Jeltsch, M.; et al. Overexpression of vascular endothelial growth factor-B in mouse heart alters cardiac lipid metabolism and induces myocardial hypertrophy. Circ. Res. 2008, 103, 1018-1026.
51. Zentilin, L.; Puligadda, U.; Lionetti, V.; Zacchigna, S.; Collesi, C.; Pattarini, L.; Ruozi, G.; Camporesi, S.; Sinagra, G.; Pepe, M.; et al. Cardiomyocyte VEGFR-1 activation by VEGF-B induces compensatory hypertrophy and preserves cardiac function after myocardial infarction. Faseb J. 2010, 24, 1467-1478.
52. Misteli, H.; Wolff, T.; Fuglistaler, P.; Gianni-Barrera, R.; Gurke, L.; Heberer, M.; Banfi, A. High-throughput flow cytometry purification of transduced progenitors expressing defined levels of vascular endothelial growth factor induces controlled angiogenesis in vivo. Stem Cells 2010, 28, 611-619.
53. Wolff, T.; Mujagic, E.; Gianni-Barrera, R.; Fueglistaler, P.; Helmrich, U.; Misteli, H.; Gurke, L.; Heberer, M.; Banfi, A. FACS-purified myoblasts producing controlled VEGF levels induce safe and stable angiogenesis in chronic hind limb ischemia. J. Cell. Mol. Med. 2012, 16, 107-117.
54. Helmrich, U.; Marsano, A.; Melly, L.; Wolff, T.; Christ, L.; Heberer, M.; Scherberich, A.; Martin, I.; Banfi, A. Generation of human adult mesenchymal stromal/stem cells expressing defined xenogenic vascular endothelial growth factor levels by optimized transduction and flow cytometry purification. Tissue Eng. Part C. Methods 2012, 18, 283-292.
55. Melly, L.; Marsano, A.; Frobert, A.; Boccardo, S.; Helmrich, U.; Heberer, M.; Eckstein, F.S.; Carrel, T.P.; Giraud, M.; Tevaearai, H.T.; et al. Controlled angiogenesis in the heart by cell-based expression of specific VEGF levels. Hum. Gene Ther. Methods 2012, in press.
56. Iyer, R.K.; Chiu, L.L.; Reis, L.A.; Radisic, M. Engineered cardiac tissues. Curr. Opin. Biotechnol. 2011, 22, 706-714.
57. Miyahara, Y.; Nagaya, N.; Kataoka, M.; Yanagawa, B.; Tanaka, K.; Hao, H.; Ishino, K.; Ishida, H.; Shimizu, T.; Kangawa, K.; et al. Monolayered mesenchymal stem cells repair scarred myocardium after myocardial infarction. Nat. Med. 2006, 12, 459-465.
58. Shimizu, T.; Sekine, H.; Yang, J.; Isoi, Y.; Yamato, M.; Kikuchi, A.; Kobayashi, E.; Okano, T. Polysurgery of cell sheet grafts overcomes diffusion limits to produce thick, vascularized myocardial tissues. FASEB J. 2006, 20, 708-710.
59. Zhang, M.; Methot, D.; Poppa, V.; Fujio, Y.; Walsh, K.; Murry, C.E. Cardiomyocyte grafting for cardiac repair: Graft cell death and anti-death strategies. J. Mol. Cell. Cardiol. 2001, 33, 907-921.
60. Zimmermann, W.H.; Didie, M.; Doker, S.; Melnychenko, I.; Naito, H.; Rogge, C.; Tiburcy, M.; Eschenhagen, T. Heart muscle engineering: an update on cardiac muscle replacement therapy. Cardiovasc. Res. 2006, 71, 419-429.
61. Caspi, O.; Lesman, A.; Basevitch, Y.; Gepstein, A.; Arbel, G.; Habib, I.H.; Gepstein, L.; Levenberg, S., Tissue engineering of vascularized cardiac muscle from human embryonic stem cells. Circ. Res. 2007, 100, 263-272.
62. Laugwitz, K.L.; Moretti, A.; Lam, J.; Gruber, P.; Chen, Y.; Woodard, S.; Lin, L.Z.; Cai, C.L.; Lu, M.M.; Reth, M.; et al. Postnatal isl1+ cardioblasts enter fully differentiated cardiomyocyte lineages. Nature 2005, 433, 647-653.
63. Vunjak-Novakovic, G.; Tandon, N.; Godier, A.; Maidhof, R.; Marsano, A.; Martens, T.P.; Radisic, M. Challenges in cardiac tissue engineering. Tissue Eng. Part B Rev. 2010, 16, 169-187.
64. Hamdi, H.; Planat-Benard, V.; Bel, A.; Puymirat, E.; Geha, R.; Pidial, L.; Nematalla, H.; Bellamy, V.; Bouaziz, P.; Peyrard, S.; et al. Epicardial adipose stem cell sheets results in greater postinfarction survival than intramyocardial injections. Cardiovasc. Res. 2011, 91, 483-491.
65. Leor, J.; Aboulafia-Etzion, S.; Dar, A.; Shapiro, L.; Barbash, I.M.; Battler, A.; Granot, Y.; Cohen, S. Bioengineered cardiac grafts: A new approach to repair the infarcted myocardium? Circulation 2000, 102, III56-III61.
66. Li, R.K.; Jia, Z.Q.; Weisel, R.D.; Mickle, D.A.; Choi, A.; Yau, T.M. Survival and function of bioengineered cardiac grafts. Circulation 1999, 100, II63-II69.
67. Dvir, T.; Kedem, A.; Ruvinov, E.; Levy, O.; Freeman, I.; Landa, N.; Holbova, R.; Feinberg, M.S.; Dror, S.; Etzion, Y.; et al. Prevascularization of cardiac patch on the omentum improves its therapeutic outcome. Proc. Natl. Acad. Sci. USA 2009, 106, 14990-14995.
68. Iyer, R.K.; Chiu, L.L.; Radisic, M. Microfabricated poly(ethylene glycol) templates enable rapid screening of triculture conditions for cardiac tissue engineering. J. Biomed. Mater. Res. Part A 2009, 89, 616-631.
69. Iyer, R.K.; Chiu, L.L.; Vunjak-Novakovic, G.; Radisic, M. Biofabrication enables efficient interrogation and optimization of sequential culture of endothelial cells, fibroblasts and cardiomyocytes for formation of vascular cords in cardiac tissue engineering. Biofabrication 2012, 4, 035002.
70. Lesman, A.; Habib, M.; Caspi, O.; Gepstein, A.; Arbel, G.; Levenberg, S.; Gepstein, L. Transplantation of a tissue-engineered human vascularized cardiac muscle. Tissue Eng. Part A 2010, 16, 115-125.
71. Madden, L.R.; Mortisen, D.J.; Sussman, E.M.; Dupras, S.K.; Fugate, J.A.; Cuy, J.L.; Hauch, K.D.; Laflamme, M.A.; Murry, C.E.; Ratner, B.D. Proangiogenic scaffolds as functional templates for cardiac tissue engineering. Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 15211-15216.
72. Miyagi, Y.; Chiu, L.L.; Cimini, M.; Weisel, R.D.; Radisic, M.; Li, R.K. Biodegradable collagen patch with covalently immobilized VEGF for myocardial repair. Biomaterials 2011, 32, 1280-1290.
73. Marsano, A.; Maidhof, R.; Luo, J.; Fujikara, K.; Konofagou, E.E.; Banfi, A.; Vunjak-Novakovic, G. The effect of controlled expression of VEGF by transduced myoblasts in a cardiac patch on vascularization in a mouse model of myocardial infarction. Biomaterials 2013, 34, 393-401.